α6β2* and α4β2* nicotinic receptors both regulate dopamine signaling with increased nigrostriatal damage: Relevance to Parkinson's disease

Molecular Pharmacology

Volumn 78, Issue 5, 2010, Pages 971-980

  Perez, Xiomara A ^a   Bordia, Tanuja ^a   McIntosh, J Michael ^b   Quik, Maryka ^a  

^a SRI INTERNATIONAL   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA4BETA2; NICOTINIC RECEPTOR ALPHA6BETA2; UNCLASSIFIED DRUG; ALPHA6BETA2 NACHR PROTEIN, RAT; DOPAMINE TRANSPORTER; NICOTINIC RECEPTOR BLOCKING AGENT; OXIDOPAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; DOPAMINE RELEASE; DOPAMINE UPTAKE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; EVOKED RESPONSE; MALE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; STRIATONIGRAL DEGENERATION; ACTION POTENTIAL; ANIMAL; AUTORADIOGRAPHY; CORPUS STRIATUM; METABOLISM; NERVE CELL; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; SUBSTANTIA NIGRA;

ACTION POTENTIALS; ANIMALS; AUTORADIOGRAPHY; BINDING SITES; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; MALE; NEURONS; NICOTINIC ANTAGONISTS; OXIDOPAMINE; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NICOTINIC; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA;

EID: 77958147569     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.110.067561     Document Type: Article

References (41)

1. Artymyshyn R, Smith A, and Wolfe BB (1990) The use of 3H standards in 125I autoradiography. J Neurosci Methods 32:185-192.
2. Bergstrom BP, Schertz KE, Weirick T, Nafziger B, Takacs SA, Lopes KO, Massa KJ, Walker QD, and Garris PA (2001) Partial, graded losses of dopamine terminals in the rat caudate-putamen: an animal model for the study of compensatory adaptation in preclinical parkinsonism. J Neurosci Methods 106:15-28. (Pubitemid 32193011)
3. Bordia T, Campos C, Huang L, and Quik M (2008) Continuous and intermittent nicotine treatment reduces L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson's disease. J Pharmacol Exp Ther 327:239-247.
4. Bordia T, Grady SR, McIntosh JM, and Quik M (2007) Nigrostriatal damage preferentially decreases a subpopulation of alpha6beta2* nAChRs in mouse, monkey, and Parkinson's disease striatum. Mol Pharmacol 72:52-61. (Pubitemid 46998524)
5. Cenci MA and Lundblad M (2007) Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice. Curr Protoc Neurosci Chapter 9:Unit 9.25.
6. Cragg SJ, Nicholson C, Kume-Kick J, Tao L, and Rice ME (2001) Dopamine-mediated volume transmission in midbrain is regulated by distinct extracellular geometry and uptake. J Neurophysiol 85:1761-1771. (Pubitemid 32280614)
7. Davie CA (2008) A review of Parkinson's disease. Br Med Bull 86:109-127.
8. Exley R, Clements MA, Hartung H, McIntosh JM, and Cragg SJ (2008) Alpha6-containing nicotinic acetylcholine receptors dominate the nicotine control of dopamine neurotransmission in nucleus accumbens. Neuropsychopharmacology 33:2158-2166. (Pubitemid 351992087)
9. Exley R and Cragg SJ (2008) Presynaptic nicotinic receptors: a dynamic and diverse cholinergic filter of striatal dopamine neurotransmission. Br J Pharmacol 153 (Suppl 1):S283-S297. (Pubitemid 351340986)
10. Garris PA, Walker QD, and Wightman RM (1997) Dopamine release and uptake rates both decrease in the partially denervated striatum in proportion to the loss of dopamine terminals. Brain Res 753:225-234.
11. Gotti C, Clementi F, Fornari A, Gaimarri A, Guiducci S, Manfredi I, Moretti M, Pedrazzi P, Pucci L, and ZoliM(2009) Structural and functional diversity of native brain neuronal nicotinic receptors. Biochem Pharmacol 78:703-711.
12. Grady SR, Salminen O, Laverty DC, Whiteaker P, McIntosh JM, Collins AC, and Marks MJ (2007) The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum. Biochem Pharmacol 74:1235-1246. (Pubitemid 47417935)
13. Heien ML and Wightman RM (2006) Phasic dopamine signaling during behavior, reward, and disease states. CNS Neurol Disord Drug Targets 5:99-108.
14. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington DC.
15. John CE, Budygin EA, Mateo Y, and Jones SR (2006) Neurochemical characterization of the release and uptake of dopamine in ventral tegmental area and serotonin in substantia nigra of the mouse. J Neurochem 96:267-282.
16. Livingstone PD and Wonnacott S (2009) Nicotinic acetylcholine receptors and the ascending dopamine pathways. Biochem Pharmacol 78:744-755.
17. McCallum SE, Parameswaran N, Bordia T, McIntosh JM, Grady SR, and Quik M (2005) Decrease in alpha3*/alpha6* nicotinic receptors but not nicotine-evoked dopamine release in monkey brain after nigrostriatal damage. Mol Pharmacol 68:737-746. (Pubitemid 41206027)
18. McCallum SE, Parameswaran N, Perez XA, Bao S, McIntosh JM, Grady SR, and Quik M (2006) Compensation in pre-synaptic dopaminergic function following nigrostriatal damage in primates. J Neurochem 96:960-972. (Pubitemid 351678496)
19. Meyer EL, Yoshikami D, and McIntosh JM (2008) The neuronal nicotinic acetylcholine receptors alpha 4* and alpha 6* differentially modulate dopamine release in mouse striatal slices. J Neurochem 105:1761-1769. (Pubitemid 351678494)
20. Perez XA, Bordia T, McIntosh JM, Grady SR, and Quik M (2008a) Long-term nicotine treatment differentially regulates striatal alpha6alpha4beta2* and alpha6(nonalpha4)beta2* nAChR expression and function. Mol Pharmacol 74: 844-853.
21. Perez XA, O'Leary KT, Parameswaran N, McIntosh JM, and Quik M (2009) Prominent role of alpha3/alpha6beta2* nAChRs in regulating evoked dopamine release in primate putamen: effect of long-term nicotine treatment. Mol Pharmacol 75:938-946.
22. Perez XA, Parameswaran N, Huang LZ, O'Leary KT, and Quik M (2008b) Presynaptic dopaminergic compensation after moderate nigrostriatal damage in nonhuman primates. J Neurochem 105:1861-1872. (Pubitemid 351678496)
23. Picciotto MR and Zoli M (2008) Neuroprotection via nAChRs: the role of nAChRs in neurodegenerative disorders such as Alzheimer's and Parkinson's disease. Front Biosci 13:492-504.
24. Quik M, Cox H, Parameswaran N, O'Leary K, Langston JW, and Di Monte D (2007a) Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys. Ann Neurol 62:588-596.
25. Quik M, Huang LZ, Parameswaran N, Bordia T, Campos C, and Perez XA (2009) Multiple roles for nicotine in Parkinson's disease. Biochem Pharmacol 78:677-685.
26. Quik M, O'Neill M, and Perez XA (2007b) Nicotine neuroprotection against nigrostriatal damage: importance of the animal model. Trends Pharmacol Sci 28:229-235. (Pubitemid 46680334)
27. Quik M, Polonskaya Y, Kulak JM, and McIntosh JM (2001) Vulnerability of 125I-alpha-conotoxin MII binding sites to nigrostriatal damage in monkey. J Neurosci 21:5494-5500. (Pubitemid 32692147)
28. Quik M, Sum JD, Whiteaker P, McCallum SE, Marks MJ, Musachio J, McIntosh JM, Collins AC, and Grady SR (2003) Differential declines in striatal nicotinic receptor subtype function after nigrostriatal damage in mice. Mol Pharmacol 63:1169-1179. (Pubitemid 36529935)
29. Rice ME and Cragg SJ (2004) Nicotine amplifies reward-related dopamine signals in striatum. Nat Neurosci 7:583-584.
30. Sandberg SG and Phillips PEM (2009) Phasic dopaminergic signaling: implications for Parkinson's disease, in Cortico-Subcortical Dynamics in Parkinson's Disease pp 36-59, Humana Press, Totowa, NJ.
31. Schallert T, Fleming SM, Leasure JL, Tillerson JL, and Bland ST (2000) CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 39:777-787. (Pubitemid 30103682)
32. Singh N, Pillay V, and Choonara YE (2007) Advances in the treatment of Parkinson's disease. Prog Neurobiol 81:29-44.
33. Snyder GL, Keller RW Jr, and Zigmond MJ (1990) Dopamine efflux from striatal slices after intracerebral 6-hydroxydopamine: evidence for compensatory hyperactivity of residual terminals. J Pharmacol Exp Ther 253:867-876.
34. Wightman RM and Zimmerman JB (1990) Control of dopamine extracellular concentration in rat striatum by impulse flow and uptake. Brain Res Brain Res Rev 15:135-144.
35. Zhang H and Sulzer D (2004) Frequency-dependent modulation of dopamine release by nicotine. Nat Neurosci 7:581-582. (Pubitemid 38691893)
36. Zhang L, Doyon WM, Clark JJ, Phillips PE, and Dani JA (2009a) Controls of tonic and phasic dopamine transmission in the dorsal and ventral striatum. Mol Pharmacol 76:396-404.
37. Zhang T, Zhang L, Liang Y, Siapas AG, Zhou FM, and Dani JA (2009b) Dopamine signaling differences in the nucleus accumbens and dorsal striatum exploited by nicotine. J Neurosci 29:4035-4043.
38. Zhou FM, Liang Y, and Dani JA (2001) Endogenous nicotinic cholinergic activity regulates dopamine release in the striatum. Nat Neurosci 4:1224-1229. (Pubitemid 33135628)
39. Zhou FM, Wilson CJ, and Dani JA (2002) Cholinergic interneuron characteristics and nicotinic properties in the striatum. J Neurobiol 53:590-605.
40. Zigmond MJ, Abercrombie ED, Berger TW, Grace AA, and Stricker EM (1990) Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci 13:290-296.
41. Zigmond MJ, Acheson AL, Stachowiak MK, and Stricker EM (1984) Neurochemical compensation after nigrostriatal bundle injury in an animal model of preclinical parkinsonism. Arch Neurol 41:856-861.